Question to Daniel if I may. Perhaps for the next presentation if the answer will take too long here.
I am interested in your thoughts re Bisantrene vs liposomal Doxorubicin. As I understand it they both have marked reduced cardio toxicity compared to standard and are both well advanced in the clinic. I would value your thoughts as to why Bisantrene may be expected to be better and why oncologists would swap one for the other on a new trial design.
thanks
General Comments / Chat, page-86
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.75 |
Change
-0.040(2.23%) |
Mkt cap ! $297.9M | |||
| Open | High | Low | Value | Volume |
| $1.79 | $1.79 | $1.72 | $146.2K | 83.61K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2901 | $1.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.75 | 994 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.74 |
Change
-0.040 ( 1.51 %) |
||||
| Open | High | Low | Volume | ||
| $1.76 | $1.77 | $1.72 | 23546 | ||
| Last updated 15.56pm 17/06/2024 ? | |||||
| RAC (ASX) Chart |
